Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly

It is quite rare that Cushing's disease shows acromegaly, and no pharmacotherapy has yet been discussed. A 21-year-old woman was diagnosed with Cushing's disease and underwent trans-sphenoidal surgery. Five years later, she was diagnosed with recurrent Cushing's disease and biochemica...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukunaga, Kensaku, Imachi, Hitomi, Sato, Seisuke, Kobayashi, Toshihiro, Yoshioka, Yuki, Saheki, Takanobu, Ban, Natsuki, Urushihara, Kurumi, Lyu, Jingya, Dong, Tao, Ishikawa, Ryou, Kadota, Kyuichi, Haba, Reiji, Inoshita, Naoko, Murao, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079926/
https://www.ncbi.nlm.nih.gov/pubmed/33162471
http://dx.doi.org/10.2169/internalmedicine.4663-20
Descripción
Sumario:It is quite rare that Cushing's disease shows acromegaly, and no pharmacotherapy has yet been discussed. A 21-year-old woman was diagnosed with Cushing's disease and underwent trans-sphenoidal surgery. Five years later, she was diagnosed with recurrent Cushing's disease and biochemical acromegaly because of elevated levels of serum growth hormone (GH), plasma insulin-like growth factor-1, plasma adrenocorticotropic hormone (ACTH), and the 24-hour urinary excretion of free cortisol. After treatment initiation with pasireotide-long-acting release (LAR), both the ACTH and GH declined. Our case is the first to show the efficacy of pasireotide-LAR in controlling both Cushing's disease and acromegaly.

Ejemplares similares